Abstract:The voltage-gated calcium channels CaV3.1-3.3 constitute the T-type subfamily, whose dysfunctions are associated with epilepsy, psychiatric disorders, and chronic pain. The unique properties of low-voltage-activation, faster inactivation, and slower deactivation of these channels support their role in modulation of cellular excitability and low-threshold firing. Thus, selective T-type calcium channel antagonists are highly sought after. Here, we explored Ugi-azide multicomponent reaction products to identify compounds targeting T-type calcium channel. Of the 46 compounds tested, an analog of benzimidazolonepiperidine-5bk (1-{1-[(R)-{1-[(1S)-1-phenylethyl]-1H-1,2,3,4-tetrazol-5-yl}(thiophen-3-yl)methyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one) modulated depolarization-induced calcium influx in rat sensory neurons. Modulation of T-type calcium channels by 5bk was further confirmed in whole-cell patch clamp assays in dorsal root ganglion (DRG) neurons, where pharmacological isolation of T-type currents led to a time- and concentration-dependent regulation with a low micromolar IC50. Lack of an acute effect of 5bk argues against a direct action on T-type channels. Genetic knockdown revealed CaV3.2 to be the isoform preferentially modulated by 5bk. High voltage-gated calcium, as well as tetrodotoxin-sensitive and -resistant sodium, channels were unaffected by 5bk. 5bk inhibited spontaneous excitatory postsynaptic currents and depolarization-evoked release of calcitonin gene-related peptide from lumbar spinal cord slices. Notably, 5bk did not bind human mu, delta, or kappa opioid receptors. 5bk reversed mechanical allodynia in rat models of HIV-associated neuropathy, chemotherapy-induced peripheral neuropathy, and spinal nerve ligation-induced neuropathy, without effects on locomotion or anxiety. Thus, 5bk represents a novel T-type modulator that could be used to develop nonaddictive pain therapeutics.

Discovery of α‐Obscurine Derivatives as Novel Cav3.1 Calcium Channel Blockers

Selective Inhibition of TRPM2 Channel by Two Novel Synthesized ADPR Analogues

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

Synthesis of a Series of 4-Benzyloxyaniline Analogues As Neuronal N-type Calcium Channel Blockers with Improved Anticonvulsant and Analgesic Properties.

A modulator of the low-voltage activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies.

Structurally modified Cyclovirobuxine-D Buxus alkaloids as effective analgesic agents through Cav3.2 T-Type calcium channel inhibition

The Discovery of Novel ACA Derivatives As Specific TRPM2 Inhibitors That Reduce Ischemic Injury Both in Vitro and in Vivo.

Monoterpene Indole Alkaloids with Ca(v)3.1 T-Type Calcium Channel Inhibitory Activity from Catharanthus roseus

Discovery of a novel K V 7.2/7.3 channels agonist for the treatment of neuropathic pain

Discovery of Triazolopyrimidine Derivatives as Selective P2X3 Receptor Antagonists Binding to an Unprecedented Allosteric Site as Evidenced by Cryo-Electron Microscopy

Natural product inspired optimization of a selective TRPV6 calcium channel inhibitor

Monoterpene Indole Alkaloids with Cav3.1 T-Type Calcium Channel Inhibitory Activity from Catharanthus roseus

Synthesis and biological evaluation of lycoctonine derivatives with cardiotonic and calcium channels inhibitory activities

Identification and Optimization of 2‐aminobenzimidazole Derivatives As Novel Inhibitors of TRPC4 and TRPC5 Channels

Discovery of a novel series of pyridone amides as Na V 1.8 inhibitors

Structural Basis for Human Cav3.2 Inhibition by Selective Antagonists

Discovery of 1-Aryloxyethyl Piperazine Derivatives As Kv1.5 Potassium Channel Inhibitors (part I).

Structural basis for human Ca v 3.2 inhibition by selective antagonists

Naphthylisoquinoline alkaloids, a new structural template inhibitor of Nav1.7 sodium channel

Discovery of a Novel Series of Pyridone Amides As NaV1.8 Inhibitors.

Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing.